Lipoprotein(a) as a cardiovascular risk factor: current status

20101,763 citationsJournal Articlehybrid Open Access

Authors

Børge G. Nordestgaard · Herlev Hospital

M. John Chapman · Pitié-Salpêtrière Hospital

Kausik K. Ray · St George's, University of London

Jan Borén · University of Gothenburg

Felicita Andreotti · Catholic University of America

Gerald F. Watts · University of Western Australia

Henry N. Ginsberg

Abstract

We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.

Topics & Keywords

Lipoproteins and Cardiovascular Health Cancer, Lipids, and Metabolism Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 31, Issue 23, pp. 2844-2853

DOI: 10.1093/eurheartj/ehq386

Field-Weighted Citation Impact: 71.00